Mirabegron Zentiva (Mirabegron)

Mirabegron selectively activates beta‑3 adrenergic receptors in the bladder’s detrusor muscle. This activation raises intracellular cAMP levels, causing the muscle to relax during the bladder‑filling phase, which increases functional bladder capacity and lessens involuntary contractions that trigger urgency and leakage.

The prescribed dose of mirabegron is determined by the treating clinician based on the patient’s condition, response, and any concomitant therapies. The prescriber will select the appropriate starting dose and may adjust it according to therapeutic goals and tolerability.

Safety data for mirabegron during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mirabegron Zentiva. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class—beta‑3 adrenergic agonists—whereas antimuscarinics block muscarinic receptors. Mirabegron often has a lower incidence of dry mouth and constipation, common side effects of antimuscarinics, but may be associated with higher rates of hypertension. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Store Mirabegron Zentiva below 25 °C in its original packaging, protecting it from moisture and direct heat. Keep the container tightly closed and out of reach of children. No special refrigeration is required for this oral tablet formulation.

Mirabegron Zentiva is taken orally, usually once daily. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include marked hypertension, acute urinary retention that may require catheterisation, and severe allergic reactions such as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience sudden high blood pressure, inability to urinate, or signs of a severe allergic response.

Mirabegron should be avoided in individuals with uncontrolled hypertension, severe urinary retention or known bladder outlet obstruction, and in patients with a documented hypersensitivity to mirabegron or any excipients in the tablet. Caution is also advised for those taking strong CYP2D6 inhibitors.